Recent Updates
Recently added Catalysts

SCH 900518 Biologic: Peginterferon alfa-2b

Phase 1

Hepatitis C, Chronic | Small molecule | Infectious Disease |Merck & Company, Inc.|Last Updated: Feb 9, 2015

Target and mechanism

ModalitySmall molecule

Also known as Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron), Drug: SCH 900518 Biologic: Peginterferon alfa-2b

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment41

FDA Designations

No designations recorded

Clinical trial landscape

SCH 900518 Biologic: Peginterferon alfa-2b · 1 trial · 1 indication

Phase 1 1
NCT01081158Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)Hepatitis C, Chronic
COMPLETED41 Analytics
PHASE1COMPLETED
Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)
Hepatitis C, Chronic
NCT0108115841
Unlock trial analytics

Study Endpoints

Primary Endpoints

Safety and tolerability were to be assessed by collecting adverse events (AEs), vital signs, electrocardiograms (ECGs), physical examinations, urinalysis, and safety laboratory tests.
Screening Period: 90 days, Period 1: 7 days, Washout: 4 weeks, Period 2: 14 days, Standard of Care with PegIntron and ribavirin: 84 days

Secondary Endpoints

Log change in HCV-RNA from baseline. Ctrough of SCH 900518 resulting in mean HCV RNA decrease > 2 log10 IU/mL. Ctrough of SCH 900518+PEG resulting in HCV-RNA < LOQ. SCH 900518 PK: Cmax, Tmax, AUC, Ctrough, t½, R, CL/F, Vd/F. PEG and RTV: Ctrough
Period 1: 7 days, Washout: 4 weeks, Period 2: 14 Days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Treatment-naïve 800 mg TIDEXPERIMENTALPeriod 1: SCH 900518 (800 mg TID) or placebo for 7 days Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 µg/kg QW) or placebo + PegIntron for 14 days.
Treatment-experienced: 800 mg TIDEXPERIMENTALPeriod 1: SCH 900518 (800 mg TID) or placebo for 7 days Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 ug/kg QW) or placebo + PegIntron for 14 days
Treatment-naïve: 400 mg + RTV BIDEXPERIMENTALPeriod 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days. Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days.
Treatment-experienced: 400 mg + RTV BIDEXPERIMENTALPeriod 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days. Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days.

Interventions

NameTypeDescription
Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)DRUGDrug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron) Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days . Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly.
Drug: SCH 900518 Biologic: Peginterferon alfa-2bDRUGDrug: SCH 900518 Biologic: Peginterferon alfa-2b Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly.
Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)DRUGDrug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron) Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days. Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days.
Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)DRUGDrug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron) Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days. Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Subject infected with HCV genotype 1 (any sub-type) virus who is: * treatment naïve (eg. to interferon and ribavirin); or * treatment experienced (non-responder and relapser): subject who received interferon based therapy and continued to have detectable HCV RNA levels at...

Unlock Eligibility Criteria

Frequently asked questions about SCH 900518 Biologic: Peginterferon alfa-2b

What is SCH 900518 Biologic: Peginterferon alfa-2b used for?

SCH 900518 Biologic: Peginterferon alfa-2b is being studied for the treatment of chronic hepatitis C, specifically in patients infected with HCV genotype 1. It is an investigational therapy being developed by Merck & Company, Inc. (MRK) and has completed a Phase 1 clinical trial.

Who is developing SCH 900518 Biologic: Peginterferon alfa-2b?

SCH 900518 Biologic: Peginterferon alfa-2b is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. Merck is responsible for the clinical development of this investigational treatment for chronic hepatitis C.

What phase is SCH 900518 Biologic: Peginterferon alfa-2b in?

SCH 900518 Biologic: Peginterferon alfa-2b is in Phase 1 clinical development. It has completed one Phase 1 trial and is not yet approved by the FDA. The drug remains investigational for the treatment of chronic hepatitis C.

What clinical trials is SCH 900518 Biologic: Peginterferon alfa-2b in?

SCH 900518 Biologic: Peginterferon alfa-2b has been evaluated in a completed Phase 1 trial, NCT01081158, titled "Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)." The trial enrolled 41 participants and was randomized, double-blind, and controlled.

Is SCH 900518 Biologic: Peginterferon alfa-2b the same as PegIntron?

SCH 900518 Biologic: Peginterferon alfa-2b is also known as PegIntron. PegIntron is the brand name for peginterferon alfa-2b, which is being studied in combination with SCH 900518 for chronic hepatitis C. The full investigational name reflects this combination approach.